© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 8, 658-662,
April 21, 1993
© 1993 Oxford University Press
Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group
Medizinische Klinik und Poliklinik V, University of Heidelberg Heidelberg, Federal Republic of Germany
University of California Cancer Center San Diego, Calif
Universitätsklinik für Innere Medizin Innsbruck, Austria
Institut Jules Bordet, Clinique et Laboratoire d'Hématologie Brussels, Belgium
Academisch Ziekenhuis Rotterdam Rotterdam, The Netherlands
Academisch Ziekenhuis Nijmegen Nijmegen, The Netherlands
Universitätsklinik für Innere Medizin I Wien, Austria
Università degli Studi di Bologna Bologna, Italy
Pathologisches Institut, University of Kiel Kiel, Federal Republic of Germany
EORTC Data Center Brussels, Belgium
Hôtel-Dieu de Paris Paris, France
Correspondence to: Hartmut D{diaeresis}hner. M.D., Medizinische Klinik und Poliklinik V, University of Heidelberg, Hospitalstrasse 3, 6900 Heidelberg, FRG.
Background: B-cell prolymphocytic leukemias or T-cell prolymphocytic leukemias are aggressive variants of chronic lymphoid leukemias. The small studies conducted to date have shown median survival durations of approximately 3 years for patients who have B-cell prolymphocytic leukemia and 7.5 months for those who have T-cell prolymphocytic leukemia, compared with about 8 years for patients who have chronic lymphocytic leukemia. In chronic lymphocytic leukemia, chemotherapy consisting of alkylating agents such as cyclophosphamide and chlorambucil combined with prednisone has achieved overall response rates of 50% to 70%, but this regimen has resulted in response rates of less than 25% in prolymphocytic leukemia. Pentostatin (2'-deoxycoformycin; DCF) is a purine analogue that has shown activity in treatment of chronic lymphoid malignancies. Purpose: This prospective phase II trial by the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer was performed to assess the activity and toxicity of DCF in prolymphocytic leukemia. Methods: Twenty patients with B-cell or T-cell prolymphocytic leukemia were given DCF at a dosage of 4 mg/m2 intravenously once a week for 3 weeks, then every other week for three doses. Patients who had at least partial response received maintenance therapy once a month for a maximum of 6 months. Fourteen patients had B-cell prolymphocytic leukemia, and six had T-cell prolymphocytic leukemia, as evidenced by morphologic and immunologic criteria; three were previously untreated, eight had been given one or two chemotherapeutic regimens, and nine had been given more than two. Results: One patient died of an unknown cause during the first 6 weeks of treatment, and one died of disseminated toxoplasmosis during the period of maintenance therapy, 5 months after achieving partial remission. Nine (45% response rate) of the 20 patients achieved partial remission, including seven (50%) of 14 with B-cell prolymphocytic leukemia and two (33%) of six with T-cell prolymphocytic leukemia. The median duration of response was 9 months (range, 2–30 months); for patients with B-cell prolymphocytic leukemia, the median remission duration was 12 months. No complete remission was observed. Toxic effects included nausea and vomiting (30%), infections (30%), and transient increase in liver enzymes (35%) and increatinine (20%) levels. Eight patients experienced thrombocytopenia, the major hematologic toxic effect; four had grade 3 or 4 toxic effects. Conclusion: DCF is active in prolymphocytic leukemia, even as salvage therapy in patients who had received multiple prior chemotherapeutic regimens. Implications: Trials using DCF or other purine analogues alone or in combination with standard chemotherapeutic agents in front-line or salvage therapy are warranted to improve the prognosis of patients with prolymphocytic leukemia. [J Natl Cancer Inst 85:658-662, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Keating, B. Cazin, S. Coutre, R. Birhiray, T. Kovacsovics, W. Langer, B. Leber, T. Maughan, K. Rai, G. Tjonnfjord, et al. Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed J. Clin. Oncol., January 1, 2002; 20(1): 205 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kalil and B. D. Cheson Chronic Lymphocytic Leukemia Oncologist, October 1, 1999; 4(5): 352 - 369. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. D. Jennings and K. A. Foon Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy Blood, October 15, 1997; 90(8): 2863 - 2892. [Full Text] [PDF]
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders Oncologist, June 1, 1996; 1(3): 125 - 139. [Abstract] [Full Text] [PDF]
|
|